search
Back to results

HU007 in Patients With Dry Eye Syndrome

Primary Purpose

Dry Eye Disease

Status
Recruiting
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
HU007
Restasis
Moisview Eye drop
Sponsored by
Huons Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye Disease

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Age over 19 Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 in at least one of both eyes Volunteer who have had more than one symptom of dry eye disease for at least 3 month before screening visit. Exclusion Criteria: The patients with clinically significant ocular disorders affected the test result Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c>9% Wearing contact lenses within 72 hr of screening visit Pregnancy or Breastfeeding

Sites / Locations

  • Gyeongsang National University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

HU007

Restasis

Moisview

Arm Description

Cyclosporine 0.02%, trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks

Cyclosporine 0.05% 1 drop b.i.d at 12hr interval for 12 weeks

trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks

Outcomes

Primary Outcome Measures

change from Baseline in Corneal staining(Oxford grading) score
change from Baseline in Corneal staining(Oxford grading) score - Oxford grading:0(Absent) to 5(Severe)

Secondary Outcome Measures

Full Information

First Posted
February 14, 2023
Last Updated
March 30, 2023
Sponsor
Huons Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05743764
Brief Title
HU007 in Patients With Dry Eye Syndrome
Official Title
A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2023 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Huons Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
328 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HU007
Arm Type
Experimental
Arm Description
Cyclosporine 0.02%, trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks
Arm Title
Restasis
Arm Type
Active Comparator
Arm Description
Cyclosporine 0.05% 1 drop b.i.d at 12hr interval for 12 weeks
Arm Title
Moisview
Arm Type
Active Comparator
Arm Description
trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks
Intervention Type
Drug
Intervention Name(s)
HU007
Intervention Description
cyclosporine 0.02%, trehalose 3%
Intervention Type
Drug
Intervention Name(s)
Restasis
Intervention Description
cyclosporine 0.05%
Intervention Type
Drug
Intervention Name(s)
Moisview Eye drop
Intervention Description
trehalose 3%
Primary Outcome Measure Information:
Title
change from Baseline in Corneal staining(Oxford grading) score
Description
change from Baseline in Corneal staining(Oxford grading) score - Oxford grading:0(Absent) to 5(Severe)
Time Frame
Week12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Age over 19 Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 in at least one of both eyes Volunteer who have had more than one symptom of dry eye disease for at least 3 month before screening visit. Exclusion Criteria: The patients with clinically significant ocular disorders affected the test result Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c>9% Wearing contact lenses within 72 hr of screening visit Pregnancy or Breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dawon Park
Phone
+82-70-7492-5974
Email
dwpark@huons.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hyoju Pyo
Phone
+82-7492-5737
Email
hyoju@huosn.com
Facility Information:
Facility Name
Gyeongsang National University Hospital
City
Jinju
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
KIM

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

HU007 in Patients With Dry Eye Syndrome

We'll reach out to this number within 24 hrs